A randomized Phase II trial in patients with carcinoma of an unknown primary site

Current therapy for patients with carcinoma of an unknown primary site (CUP) is inadequate. To develop less toxic and more effective therapies for patients with CUP, a multicenter, randomized, Phase II study was conducted. Patients with CUP received either carboplatin and etoposide (CE) or a combination of paclitaxel, 5‐fluorouracil, and leucovorin (TFL).

[1]  Manuela Herman,et al.  Statistical Methods for the Analysis of Biomedical Data , 2003 .

[2]  K R Hess,et al.  Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  B. Jeremic,et al.  Short-term chemotherapy and palliative radiotherapy for elderly patients with stage IV non-small cell lung cancer: a phase II study. , 1999, Lung cancer.

[4]  M. Inbar,et al.  Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer. , 1999, American journal of clinical oncology.

[5]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[6]  N. Pavlidis,et al.  Combination Regimen with Carboplatin, Epirubicin and Etoposide in Metastatic Carcinomas of Unknown Primary Site: A Hellenic Co-Operative Oncology Group Phase II Study , 1998, Oncology.

[7]  K. Hess,et al.  Unknown primary tumors metastatic to liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Warner,et al.  A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). , 1998, British Journal of Cancer.

[9]  D. Schrijvers,et al.  Update on the taxoids and other new agents in head and neck cancer therapy. , 1998, Current opinion in oncology.

[10]  D. Strumberg,et al.  Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Y. Shyr,et al.  Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. , 1997, Seminars in oncology.

[12]  J. Hainsworth,et al.  Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Bokemeyer,et al.  A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. , 1997, Anti-cancer drugs.

[14]  P. Arese,et al.  Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study. , 1997, European journal of gynaecological oncology.

[15]  C. Hudis,et al.  Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. , 1995, Seminars in oncology.

[16]  C. Hudis,et al.  Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. , 1995, Seminars in oncology.

[17]  W. Hop,et al.  Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[19]  D. Neuberg,et al.  Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Hess,et al.  Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Ettinger.  Overview of paclitaxel (Taxol) in advanced lung cancer. , 1993, Seminars in oncology.

[22]  J. Hainsworth,et al.  Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Sporn,et al.  Empiric chemotherapy in patients with carcinoma of unknown primary site. , 1990, The American journal of medicine.

[24]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[25]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .